Earnings call briefThird-quarter 2026
Gilead Sciences GILD
Gilead Sciences puts 2028 Biktarvy net impact at approximately $1.5 billion
Gilead Sciences said it expects 2028 Biktarvy revenue to decline from 2027; the analysis is preliminary and subject to change.
GetSignal
Free on iOS and Android
Gilead Sciences said on its third-quarter call that CMS has set the price for Biktarvy at $2,600 per 30-day supply, an approximate 38% discount from the list price in the Medicare channel.
The company said its preliminary analysis puts the total net impact to Biktarvy revenue at approximately $1.5 billion in 2028, inclusive of Medicare and spillover effects to other U.S. channels. The company said the analysis is subject to change as it gets closer to 2028.
Quotes from the call
“CMS has informed us that it has set pricing for Biktarvy at $2,600 per 30-day supply, which represents an approximate 38% discount from the list price in the Medicare channel.”
“...we expect a total net impact to Biktarvy revenue of approximately $1.5 billion in 2028, reflecting the lower price in Medicare, in addition to related impacts across other U.S. channels, including Medicaid, 340B and other payer segments.”
Key facts from the call
- Biktarvy Medicare price set by CMS
- $2,600 per 30-day supply
- Discount from Medicare channel list price
- Approximate 38%
- 2028 Biktarvy net revenue impact outlook
- Reduction of approximately $1.5 billion, preliminary and subject to change
Source: Gilead Sciences' third-quarter 2026 earnings call, October 29, 2026.
Written by GetSignal with AI from the company's earnings call.
Not investment advice.